TGF-β / Smad Signaling
The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
- A8341 Go 6976Target: PKCSummary: PKCα/PKCβ1 inhibitor
- A8342 GF 109203X1 CitationTarget: PKCSummary: Protein kinase C,MLCK,PKG and PKA inhibitor
- A8604 GNF 5Target: Bcr-AblSummary: Bcr-Abl inhibitor
- A8607 PPY ATarget: Abl kinasesSummary: Abl kinases inhibitor
- B2286 K02288Target: ALKSummary: ALK inhibitor
- B1404 DCC-2036 (Rebastinib)Target: FLT3|Bcr-Abl|Tie-2|KDRSummary: Bcr-Abl inhibitor
- B5954 Dasatinib MonohydrateTarget: PDGFR|c-Kit|Bcr-Abl|SrcSummary: Inhibitor of ABL, SRC, KIT, PDGFR, and other tyrosine kinases.
- B7807 Netarsudil (AR-13324)Target: ROCKSummary: ROCK inhibitor
- B1287 Ro 31-8220Target: PKCSummary: pan-PKC inhibitor
- B2191 Dequalinium ChlorideTarget: PKC|Calcium-Activated Potassium (KCa) ChannelsSummary: anti-tumor agent and PKC inhibitor